samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

3P Biopharmaceuticals


- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment
- MG is an orphan disease which has a major unmet medical need and a large market potential 
- The drug candidate,TOL2, has already achieved several positive preclinical result



[Noáin, Spain, March 22, 2020]3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaborationonaninnovativetreatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG).

3P Biopharmaceuticals and Toleranziabegan their partnership in 2019, when 3P Biopharmaceuticals was selected to be responsible for the cell line, process and analytical methods development as well as process scale-up with the goal of achieving cGMP production in 2021 for clinical studies (Phase I and II).

Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of theautoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.

In this regard, MG represents a relatively rare autoimmune nerve and muscle disease that leads to severe muscle weakness. At present, the TOL2 candidate has achieved several positive preclinical results that indicate a favourable safety profile, no increased risk of undesirable immunological effects, and very good disease-modifying properties with potentially curative effect.

If these results can be confirmed in upcoming clinical trials, TOL2 has the potential to constitute a paradigm shift for people with MG, who are currently given only symptom-relieving treatments. Positive study results would open the door to developing effective and pioneering therapy.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: "Currently there are enormous opportunities offered by biotechnology as we can help to develop treatments for rare diseases or those without current therapeutic approaches, such as MG. Therefore, this pioneering project offers a bright hope for improving the lives of patients affected by the autoimmune neuromuscular disease Myasthenia Gravis.”

Bjorn Lowenadler, Chief Business Officer at Toleranzia, added: "We are delighted to collaborate with 3P Biopharmaceuticals for the scaling up and manufacturing of our important biological drug candidate TOL2. 3P was selected as the CDMO of choice based on their state-of-the-art infrastructure, work-force expertise and track-record”.

In order to advance to the clinic, Toleranzia will first require large-scale TOL2 production of GMP quality. 3P Biopharmaceuticals will manufacture TOL2 to allow Toleranzia to complete remaining toxicology, stability and formulation studies. 3P Biopharmaceuticals will also produce the GMP quality substance required for Phase I / II clinical studies.

Therefore, this development represents an important advance in the area of rare diseases and highlights the ability to reach the unmet needs of patients through innovation that improves and saves people´s lives.

3P Biopharmaceuticals once again demonstrates its capacity to carry out processes and manufacturing for molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.


About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market. For further information: http://www.3pbio.com/

About Toleranzia

Toleranzia is a company based in Sweden andits vision is to provide new medicines to treat and cure patients with autoimmune diseases. Toleranzia develops drugs that utilize the immune system’s own intrinsic power to treat autoimmune orphan diseases. Toleranzia´s drug candidates target the cause of the disease and can cure or greatly alleviate the disease, not only reducing the symptoms as currently available treatments do.
The company’s drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis, an orphan disease, which has a major unmet medical need and a large market potential. For further information: https://www.toleranzia.com/

3P Biopharmaceuticals contact:
Isabel García, Communications & Marketing at 3P Biopharmaceuticals
Phone: + 34 948 346 480 / email: igarcia@3pbio.com
phone +34 948 34 64 80
web www.3pbio.com/
email Polígono Mocholí, Plaza Cein, 1, 31110 Noáin, Navarra
 
Print this page
Send to a friend
   
spacer
News and Press Releases

AirBridgeCargo Airlines Expands Its Partnership With Sonoco Thermosafe To Embrace New Pegasus Uld Passive Container

AirBridgeCargo Airlines, part of Volga-Dnepr Group, expands its Master Lease Agreement with Sonoco ThermoSafe to enable its customers worldwide to transport life-saving and healthcare products within Pegasus ULD passive container (passive container – ULD capable to maintain internal temperature environment during a certain period of time without charge). The latest Sonoco addition to a sophisticated product family will guarantee secure, trackable, and reliable transportation of temperature-sensitive pharmaceutical shipments of up to 998 kg.
More info >>


White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement